BioNano Genomics (BNGOW) Stock Analysis
NASDAQHealthcareMedical - Diagnostics & Research
What BioNano Genomics does
Bionano Genomics, Inc. specializes in delivering advanced software and integrated systems for genomic analysis. Central to its offerings is the Saphyr platform, an end-to-end solution facilitating structural variant analysis through optical genome mapping. This technology aids in comprehensive genome examination and illuminates the intricacies of genetic alterations and their biological roles. The Saphyr ecosystem comprises several critical components: the Saphyr instrument, a sophisticated single-molecule imager; the Saphyr Chip, a disposable unit housing nanochannel arrays essential for DNA linearization; and specialized Bionano Prep and DNA labeling kits, which supply the necessary reagents and detailed protocols for isolating and marking ultra-high molecular weight DNA. Beyond hardware, Bionano also supplies Saphyr and Bionano compute servers for data processing. Furthermore, its NxClinical software unifies the analysis and interpretation of genomic variations derived from both microarray and next-generation sequencing data, serving both cytogenetic and molecular genetic applications. The firm extends its capabilities to include a suite of testing and laboratory services. These encompass: FirstStepDx PLUS, a chromosomal microarray designed to uncover genetic origins in patients presenting with autism spectrum disorder, developmental delays, or intellectual disabilities. Specialized testing for Fragile X syndrome (FXS). NextStepDx PLUS, an exome sequencing assay aimed at detecting genetic variants linked to pediatric developmental conditions. EpiPanelDx PLUS, a targeted genetic panel for individuals suffering from seizures, infantile spasms, encephalopathy, or febrile seizures. A PGx test capable of identifying more than 60 alleles across 11 distinct genes. Established in 2003, Bionano Genomics maintains its principal operations in San Diego, California.
Key metrics
ETFs linked to BNGOW
Broad-market and Healthcare sector ETFs an investor holding BioNano Genomics is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how BNGOW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze BNGOW in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for BioNano Genomics?
- BioNano Genomics trades under the ticker BNGOW on NASDAQ.
- Which exchange is BNGOW listed on?
- BNGOW is listed on NASDAQ.
- What sector does BioNano Genomics operate in?
- BioNano Genomics is classified in the Healthcare sector (Medical - Diagnostics & Research industry).
- How can PortView help analyze BNGOW in a portfolio?
- PortView shows BNGOW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.